Exciting news was revealed from Genzyme at the beginning of February 2014, with the announcement that their formidable multiple sclerosis drug, Alemtuzumab, had been approved for use in Mexico. Known as the brand name Lemtrada, Alemtuzumab is specifically effectual for patients with relapsing remitting multiple sclerosis, also coined RRMS. This extremely common and debilitating form[…]
Alemtuzumab Approved in Mexico for Multiple Sclerosis
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: AlemtuzumabLemtradamultiple sclerosisrelapsing remitting multiple sclerosisRRMS Feb 18, 2014
Health Canada Approves Alemtuzumab for RRMS Patients
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Health Canada Approved 2013, Monoclonal Antibodies / mAb Tags: Alemtuzumabglatiramer acetateLemtradaleukemiarelapsing remitting multiple sclerosisRRMS Dec 13, 2013
Health Canada has approved Alemtuzumab. Alemtuzumab will be marketed by Genzyme as Lemtrada for the treatment of relapsing remitting multiple sclerosis (RRMS), with active disease, who have not shown an adequate response to interferon beta or other disease-modifying therapies. Alemtuzumab is a monoclonal antibody which targets the CD52 protein. The drug was used for several[…]
Canada Approves Teriflunomide for Multiple Sclerosis
Anti-Inflammatory, Drug Research & Development API, FDA Approved 2012, Health Canada Approved 2013 Tags: multiple sclerosisrelapsing remitting multiple sclerosisRRMS Dec 06, 2013
On November 22, 2013 Health Canada approved the novel once daily pill Teriflunomide for the treatment of Multiple Sclerosis. Approved by the FDA in September of 2012, this efficacious drug is targeted for treating patients with relapsing remitting multiple sclerosis, or RRMS. The ease of use for this 14 milligram pill, taken only once a[…]
